{"id":400290,"date":"2020-12-15T13:33:40","date_gmt":"2020-12-15T18:33:40","guid":{"rendered":"http:\/\/www.marketnewsdesk.com\/?p=400290"},"modified":"2020-12-15T13:33:40","modified_gmt":"2020-12-15T18:33:40","slug":"shareholder-deadline-pawar-law-group-announces-a-securities-class-action-lawsuit-against-minerva-neurosciences-inc-nerv","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/shareholder-deadline-pawar-law-group-announces-a-securities-class-action-lawsuit-against-minerva-neurosciences-inc-nerv\/","title":{"rendered":"SHAREHOLDER DEADLINE: Pawar Law Group Announces a Securities Class Action Lawsuit Against Minerva Neurosciences, Inc.\u2013 NERV"},"content":{"rendered":"<div class=\"mw_release\">\n<p>NEW YORK, Dec.  15, 2020  (GLOBE NEWSWIRE) &#8212; Pawar Law Group announces that a class action lawsuit has been filed on behalf of shareholders who purchased shares of Minerva Neurosciences, Inc. (NASDAQ: NERV) from May 15, 2017 through November 30, 2020, inclusive (the \u201cClass Period\u201d). The lawsuit seeks to recover damages for Minerva Neurosciences, Inc. investors under the federal securities laws.<\/p>\n<p>To join the class action, go <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=JprfH56CqUw66FKRgtOabNxFFXMoYlgX9He_FMiDMk9rVKZjeBbHK7kVbM9hfFSmm4FDh3l9X5EXL06MnxaVfKHNwgyjyB4hI3GNCM1tsDlQ4IyW74D-2NHDEAHfdeeEamOmz652x7_hmxfcMgzcXg==\" rel=\"nofollow noopener noreferrer\" target=\"_blank\">here<\/a> or call Vik Pawar, Esq. toll-free at 888-589-9804 or email\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=YqqxXKdKzOIl7LbRUjUGKFGiKmnUuWzsuQ3_towSultejDIjQeN42aHEIUgJ7wlmJGvWSHRaVS5VIG8xR_BHhPvsx9S2YhKd0KfDKYLND7o=\" rel=\"nofollow noopener noreferrer\" target=\"_blank\">info@pawarlawgroup.com<\/a>\u00a0for information on the class action.<\/p>\n<p>According to the lawsuit, \u00a0defendants made false and\/or misleading statements and\/or failed to disclose that: the truth about the feedback received from the FDA concerning the \u201cend-of-Phase 2\u201d meeting; the Phase 2b study did not use the commercial formulation of roluperidone and was conducted solely outside of the United States; the failure of the Phase 3 study to meet its primary and key secondary endpoints rendered that study incapable of supporting substantial evidence of effectiveness; the Company\u2019s plan to use the combination of the Phase 2b and Phase 3 studies would be \u201chighly unlikely\u201d to support the submission of an NDA; reliance on these two trials in the submission of an NDA would lead to \u201csubstantial review issues\u201d because the trials were inadequate and not well-controlled; and as a result, the Company\u2019s public statements were materially false and misleading at all relevant times.<\/p>\n<p>If you wish to serve as lead plaintiff, you must move the Court no later than <strong>February 8, 2021<\/strong>. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation.<\/p>\n<p>No class has been certified. Until a class is certified, you are not represented by counsel unless you hire one. You may hire counsel of your choice. You may also do nothing at this time and be an absent member of the class. Your ability to share in any future recovery is not dependent upon being a lead plaintiff.<\/p>\n<p>Pawar Law Group represents investors from around the world. Attorney advertising. Prior results do not guarantee or predict a similar outcome with respect to any future matter.<br \/>&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;-<\/p>\n<p>Contact:\u00a0\u00a0<br \/>Vik Pawar, Esq.\u00a0\u00a0<br \/>Pawar Law Group\u00a0\u00a0<br \/>20 Vesey Street, Suite 1410\u00a0\u00a0<br \/>New York, NY 10007\u00a0\u00a0<br \/>Tel: (917) 261-2277\u00a0\u00a0<br \/>Fax: (212) 571-0938\u00a0\u00a0<br \/>info@pawarlawgroup.com\u00a0\u00a0<\/p>\n<p \/>\n      <img loading=\"lazy\" decoding=\"async\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODExMjcyMyMzODgyOTA4IzIwODMxNDk=\" width=\"1\" height=\"1\" \/><br \/>\n      <br \/>\n      <img loading=\"lazy\" decoding=\"async\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/ml.globenewswire.com\/release\/track\/ce88024b-43f8-4dba-9ab8-61dcc811d472\" width=\"1\" height=\"1\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>NEW YORK, Dec. 15, 2020 (GLOBE NEWSWIRE) &#8212; Pawar Law Group announces that a class action lawsuit has been filed on behalf of shareholders who purchased shares of Minerva Neurosciences, Inc. (NASDAQ: NERV) from May 15, 2017 through November 30, 2020, inclusive (the \u201cClass Period\u201d). The lawsuit seeks to recover damages for Minerva Neurosciences, Inc. investors under the federal securities laws. To join the class action, go here or call Vik Pawar, Esq. toll-free at 888-589-9804 or email\u00a0info@pawarlawgroup.com\u00a0for information on the class action. According to the lawsuit, \u00a0defendants made false and\/or misleading statements and\/or failed to disclose that: the truth about the feedback received from the FDA concerning the \u201cend-of-Phase 2\u201d meeting; the Phase 2b study did not use the &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/shareholder-deadline-pawar-law-group-announces-a-securities-class-action-lawsuit-against-minerva-neurosciences-inc-nerv\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;SHAREHOLDER DEADLINE: Pawar Law Group Announces a Securities Class Action Lawsuit Against Minerva Neurosciences, Inc.\u2013 NERV&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-400290","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.5 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>SHAREHOLDER DEADLINE: Pawar Law Group Announces a Securities Class Action Lawsuit Against Minerva Neurosciences, Inc.\u2013 NERV - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/shareholder-deadline-pawar-law-group-announces-a-securities-class-action-lawsuit-against-minerva-neurosciences-inc-nerv\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"SHAREHOLDER DEADLINE: Pawar Law Group Announces a Securities Class Action Lawsuit Against Minerva Neurosciences, Inc.\u2013 NERV - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"NEW YORK, Dec. 15, 2020 (GLOBE NEWSWIRE) &#8212; Pawar Law Group announces that a class action lawsuit has been filed on behalf of shareholders who purchased shares of Minerva Neurosciences, Inc. (NASDAQ: NERV) from May 15, 2017 through November 30, 2020, inclusive (the \u201cClass Period\u201d). The lawsuit seeks to recover damages for Minerva Neurosciences, Inc. investors under the federal securities laws. To join the class action, go here or call Vik Pawar, Esq. toll-free at 888-589-9804 or email\u00a0info@pawarlawgroup.com\u00a0for information on the class action. According to the lawsuit, \u00a0defendants made false and\/or misleading statements and\/or failed to disclose that: the truth about the feedback received from the FDA concerning the \u201cend-of-Phase 2\u201d meeting; the Phase 2b study did not use the &hellip; Continue reading &quot;SHAREHOLDER DEADLINE: Pawar Law Group Announces a Securities Class Action Lawsuit Against Minerva Neurosciences, Inc.\u2013 NERV&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/shareholder-deadline-pawar-law-group-announces-a-securities-class-action-lawsuit-against-minerva-neurosciences-inc-nerv\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2020-12-15T18:33:40+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODExMjcyMyMzODgyOTA4IzIwODMxNDk=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/shareholder-deadline-pawar-law-group-announces-a-securities-class-action-lawsuit-against-minerva-neurosciences-inc-nerv\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/shareholder-deadline-pawar-law-group-announces-a-securities-class-action-lawsuit-against-minerva-neurosciences-inc-nerv\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"SHAREHOLDER DEADLINE: Pawar Law Group Announces a Securities Class Action Lawsuit Against Minerva Neurosciences, Inc.\u2013 NERV\",\"datePublished\":\"2020-12-15T18:33:40+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/shareholder-deadline-pawar-law-group-announces-a-securities-class-action-lawsuit-against-minerva-neurosciences-inc-nerv\\\/\"},\"wordCount\":384,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/shareholder-deadline-pawar-law-group-announces-a-securities-class-action-lawsuit-against-minerva-neurosciences-inc-nerv\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODExMjcyMyMzODgyOTA4IzIwODMxNDk=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/shareholder-deadline-pawar-law-group-announces-a-securities-class-action-lawsuit-against-minerva-neurosciences-inc-nerv\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/shareholder-deadline-pawar-law-group-announces-a-securities-class-action-lawsuit-against-minerva-neurosciences-inc-nerv\\\/\",\"name\":\"SHAREHOLDER DEADLINE: Pawar Law Group Announces a Securities Class Action Lawsuit Against Minerva Neurosciences, Inc.\u2013 NERV - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/shareholder-deadline-pawar-law-group-announces-a-securities-class-action-lawsuit-against-minerva-neurosciences-inc-nerv\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/shareholder-deadline-pawar-law-group-announces-a-securities-class-action-lawsuit-against-minerva-neurosciences-inc-nerv\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODExMjcyMyMzODgyOTA4IzIwODMxNDk=\",\"datePublished\":\"2020-12-15T18:33:40+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/shareholder-deadline-pawar-law-group-announces-a-securities-class-action-lawsuit-against-minerva-neurosciences-inc-nerv\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/shareholder-deadline-pawar-law-group-announces-a-securities-class-action-lawsuit-against-minerva-neurosciences-inc-nerv\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/shareholder-deadline-pawar-law-group-announces-a-securities-class-action-lawsuit-against-minerva-neurosciences-inc-nerv\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODExMjcyMyMzODgyOTA4IzIwODMxNDk=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODExMjcyMyMzODgyOTA4IzIwODMxNDk=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/shareholder-deadline-pawar-law-group-announces-a-securities-class-action-lawsuit-against-minerva-neurosciences-inc-nerv\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"SHAREHOLDER DEADLINE: Pawar Law Group Announces a Securities Class Action Lawsuit Against Minerva Neurosciences, Inc.\u2013 NERV\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"SHAREHOLDER DEADLINE: Pawar Law Group Announces a Securities Class Action Lawsuit Against Minerva Neurosciences, Inc.\u2013 NERV - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/shareholder-deadline-pawar-law-group-announces-a-securities-class-action-lawsuit-against-minerva-neurosciences-inc-nerv\/","og_locale":"en_US","og_type":"article","og_title":"SHAREHOLDER DEADLINE: Pawar Law Group Announces a Securities Class Action Lawsuit Against Minerva Neurosciences, Inc.\u2013 NERV - Market Newsdesk","og_description":"NEW YORK, Dec. 15, 2020 (GLOBE NEWSWIRE) &#8212; Pawar Law Group announces that a class action lawsuit has been filed on behalf of shareholders who purchased shares of Minerva Neurosciences, Inc. (NASDAQ: NERV) from May 15, 2017 through November 30, 2020, inclusive (the \u201cClass Period\u201d). The lawsuit seeks to recover damages for Minerva Neurosciences, Inc. investors under the federal securities laws. To join the class action, go here or call Vik Pawar, Esq. toll-free at 888-589-9804 or email\u00a0info@pawarlawgroup.com\u00a0for information on the class action. According to the lawsuit, \u00a0defendants made false and\/or misleading statements and\/or failed to disclose that: the truth about the feedback received from the FDA concerning the \u201cend-of-Phase 2\u201d meeting; the Phase 2b study did not use the &hellip; Continue reading \"SHAREHOLDER DEADLINE: Pawar Law Group Announces a Securities Class Action Lawsuit Against Minerva Neurosciences, Inc.\u2013 NERV\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/shareholder-deadline-pawar-law-group-announces-a-securities-class-action-lawsuit-against-minerva-neurosciences-inc-nerv\/","og_site_name":"Market Newsdesk","article_published_time":"2020-12-15T18:33:40+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODExMjcyMyMzODgyOTA4IzIwODMxNDk=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/shareholder-deadline-pawar-law-group-announces-a-securities-class-action-lawsuit-against-minerva-neurosciences-inc-nerv\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/shareholder-deadline-pawar-law-group-announces-a-securities-class-action-lawsuit-against-minerva-neurosciences-inc-nerv\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"SHAREHOLDER DEADLINE: Pawar Law Group Announces a Securities Class Action Lawsuit Against Minerva Neurosciences, Inc.\u2013 NERV","datePublished":"2020-12-15T18:33:40+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/shareholder-deadline-pawar-law-group-announces-a-securities-class-action-lawsuit-against-minerva-neurosciences-inc-nerv\/"},"wordCount":384,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/shareholder-deadline-pawar-law-group-announces-a-securities-class-action-lawsuit-against-minerva-neurosciences-inc-nerv\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODExMjcyMyMzODgyOTA4IzIwODMxNDk=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/shareholder-deadline-pawar-law-group-announces-a-securities-class-action-lawsuit-against-minerva-neurosciences-inc-nerv\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/shareholder-deadline-pawar-law-group-announces-a-securities-class-action-lawsuit-against-minerva-neurosciences-inc-nerv\/","name":"SHAREHOLDER DEADLINE: Pawar Law Group Announces a Securities Class Action Lawsuit Against Minerva Neurosciences, Inc.\u2013 NERV - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/shareholder-deadline-pawar-law-group-announces-a-securities-class-action-lawsuit-against-minerva-neurosciences-inc-nerv\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/shareholder-deadline-pawar-law-group-announces-a-securities-class-action-lawsuit-against-minerva-neurosciences-inc-nerv\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODExMjcyMyMzODgyOTA4IzIwODMxNDk=","datePublished":"2020-12-15T18:33:40+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/shareholder-deadline-pawar-law-group-announces-a-securities-class-action-lawsuit-against-minerva-neurosciences-inc-nerv\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/shareholder-deadline-pawar-law-group-announces-a-securities-class-action-lawsuit-against-minerva-neurosciences-inc-nerv\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/shareholder-deadline-pawar-law-group-announces-a-securities-class-action-lawsuit-against-minerva-neurosciences-inc-nerv\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODExMjcyMyMzODgyOTA4IzIwODMxNDk=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODExMjcyMyMzODgyOTA4IzIwODMxNDk="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/shareholder-deadline-pawar-law-group-announces-a-securities-class-action-lawsuit-against-minerva-neurosciences-inc-nerv\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"SHAREHOLDER DEADLINE: Pawar Law Group Announces a Securities Class Action Lawsuit Against Minerva Neurosciences, Inc.\u2013 NERV"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/400290","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=400290"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/400290\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=400290"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=400290"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=400290"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}